Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Celcuity Q1 Earnings Call Highlights Celcuity (
NASDAQ:CELC ) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer.
On the company
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Why Celcuity Stock Popped on Monday An analyst initiated coverage of the biotech.
Why Celcuity Stock Popped Today The cancer-focused biotech published its final set of figures for 2025.
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026 As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is fundamentally decoupling from the mega-cap tech giants that dominated the previous era. In the first
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.
Investment Manager Closes Position in GEO Stock, Sells $17.6 Million Worth of Shares, According to Recent SEC Filing This corrections firm delivers facility management and reentry services to government clients in the U.S., Australia, and South Africa.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
The Great Rotation of 2026: Why Small-Cap 'Underdogs' are Finally Outpacing the Tech Titans The first quarter of 2026 has ushered in a dramatic reversal of the decade-long market hierarchy. After years of trailing in the shadow of mega-cap technology giants, small-cap stocks—the perennial underdogs of Wall Street—have surged to a commanding lead. As of March 4, 2026, the small-cap-heavy Russell 2000
